| Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance |
| 論文作者 |
Wang, CX; Long, QL; Fu, Q; Xu, QX; Fu, D; Li, Y; Gao, LB; Guo, JM; Zhang, XL; Lam, EWF; Campisi, J; Sun, Y |
| 期刊/會(huì)議名稱 |
ONCOGENE |
| 論文年度 |
2022 |
| 論文類別 |
Article |
| 摘要 |
The tumor microenvironment (TME) represents a milieu enabling cancer cells to develop malignant properties, while concerted interactions between cancer and stromal cells frequently shape an activated/reprogramed niche to accelerate pathological progression. Here we report that a soluble factor epiregulin (EREG) is produced by senescent stromal cells, which non-cell-autonomously develop the senescence-associated secretory phenotype (SASP) upon DNA damage. Genotoxicity triggers EREG expression by engaging NF-kappa B and C/EBP, a process supported by elevated chromatin accessibility and increased histone acetylation. Stromal EREG reprograms the expression profile of recipient neoplastic cells in a paracrine manner, causing upregulation of MARCHF4, a membrane-bound E3 ubiquitin ligase involved in malignant progression, specifically drug resistance. A combinational strategy that empowers EREG-specific targeting in treatment-damaged TME significantly promotes cancer therapeutic efficacy in preclinical trials, achieving response indices superior to those of solely targeting cancer cells. In clinical oncology, EREG is expressed in tumor stroma and handily measurable in circulating blood of cancer patients post-chemotherapy. This study establishes EREG as both a targetable SASP factor and a new noninvasive biomarker of treatment-damaged TME, thus disclosing its substantial value in translational medicine. [GRAPHICS] . |
| 期 |
45 |
| 卷 |
41 |
官方微信
